

## APR 11 2008

#### 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is submitted in accordance with the Requirements of Safe Medical Device systems Act 1990 and 21 CFR Sec. 807.92

510(k) Number: Applicant Information: K080884

Date Prepared:

March 2, 2008

Name:

**MTecHS** 

Division of MedTechs, LLC

Address:

111, Beaver Dam Run Durham, NC 27703 Phone: 1 877 833 3493

Contact Person:

Meghan Ath 919 619 7657

Phone Number: Fax Number:

215 474 0127

meghan@medtechs.us

### Device system Information:

Classification:

DPS/Class II/870,2340

Trade Name:

QHRV 1 - Health Assessment System

Common Name: Classification Name: HRV Analysis System Electrocardiograph

#### Substantial Equivalence:

### QHRV-1 is substantially equivalent to the following Predicate Device systems.

Hokanson ANS 2000 RR Interval Measurement K973426 Q Med Inc., Monitor One NDX HRV Analysis Function K972991 Ansore Health Management System – Boston Medical K010955

#### Intended Use:

QHRV-1 Health Assessment System has the same intended use as the legally marketed predicate device systems. The QHRV-1 System is intended for use in heart variability measurements in response to paced respiration and controlled exercises.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## APR 11 2008

MTechsHS Division of MedTechs LLC c/o Ms. Mark Job Regulatory Technology Services LLC 1394 25<sup>th</sup> Street NW Buffalo, MN 55513

Re: K080884

QHRV 1 – Health Assessment System Regulation Number: 21 CFR 870.2340 Regulation Name: Electrocardiograph Regulatory Class: Class II (two)

Product Code: DPS Dated: March 28, 2008 Received: March 31, 2008

Dear Mr. Job:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Gummumon for

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

# Indications for Use

510K Number (if known)	<u>K080884</u>
Device system Name:	QHRV 1 – Health Assessment System
Indications for Use:	The QHRV 1 – Health Assessment System is intended for (HRV) Heart Rate Variability Measurements in response to a series of paced respiration, standardized and controlled exercises. These measurements and analysis are not intended as clinical diagnosis but only to substantiate appropriate patient health assessment procedures.
Prescription Use X(Part 21 CFR 801 Subpart	Over-The-Counter Usc  (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE	BELOW THIS LINE - CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence	of CDRH, Office of Device Evaluation (ODE)
•	Bhmmumov
Ďlv	vision sign-Off) islon of Cardiovascular Devices D(k) Number KOXOLS